Nectar Lifesciences Limited has announced that the API manufacturing facility, located at U-2, Village Saidpura, Tehsil Dera Bassi, District SAS Nagar (Mohali), Punjab of the Company, has recently undergone a joint inspection conducted by the European Directorate for the Quality of Medicines & HealthCare (EDQM) and the Spanish Agency of Medicines and Medical Devices (AEMPS). This inspection aimed to assess of compliance with EuGMP standards. Following the inspection, seven observations including four critical, were noted.
The Company is in the process of preparing a Corrective Action and Preventive Action (CAPA) report to address the observations. The Company upholds quality and compliance with utmost importance and remain committed to be compliant with the cGMP quality standards.
The European regulator will conduct a re-inspection of the facility to verify the compliance and CAPA submitted which may lead to EuGMP approval.
Shares of Nectar Lifesciences Limited was last trading in BSE at Rs. 27.76 as compared to the previous close of Rs. 29.22. The total number of shares traded during the day was 47222 in over 188 trades.
The stock hit an intraday high of Rs. 29.80 and intraday low of 27.76. The net turnover during the day was Rs. 1331598.00. |
